JPT2

JPT2 (also known as HN1L) is a direct NAADP-binding protein that functions as an essential accessory subunit of the NAADP receptor complex, coupling the second messenger NAADP to Ca²⁺ release from intracellular stores. JPT2 associates with two-pore channels (TPCs) on acidic organelles and with type 1 ryanodine receptors (RYR1) on the ER, and its genetic deletion abolishes NAADP-evoked Ca²⁺ signaling, impairs Ca²⁺ microdomain formation during T cell receptor activation, and blocks SARS-CoV-2 pseudovirus translocation through the endolysosomal system (PMID:33758061, PMID:33758062). In cancer contexts, JPT2 has been reported to function as a transcriptional regulator that sustains LEPR–STAT3 signaling in breast cancer stem cells and promotes epithelial–mesenchymal transition and metastasis through AP-2γ-dependent upregulation of METTL13 in hepatocellular carcinoma (PMID:29249663, PMID:30778199). JPT2 localizes to both the nucleus and cytoplasm, consistent with roles in both Ca²⁺ signal transduction and transcriptional regulation (PMID:15094197).

1. 2004 Low

   Initial cloning of HN1L/JPT2 established that, unlike its paralog HN1 which is nuclear, JPT2 distributes to both nucleus and cytoplasm, raising the question of whether it has dual functional compartments.

   Evidence GFP-fusion protein expression and subcellular imaging in cultured cells

   PMID:15094197

   Open questions at the time

   • Single overexpression-based localization without endogenous antibody validation
   • No functional consequence of localization was demonstrated
   • Endogenous protein distribution not confirmed
2. 2017 Medium

   Two studies linked JPT2 to oncogenic signaling: one showed JPT2 sustains LEPR–STAT3 signaling in breast cancer stem cells by binding upstream regulatory sequences of STAT3, LEPR, and MIR-150, while another implicated JPT2 in MAPK pathway regulation via interaction with RASA4 in NSCLC, establishing JPT2 as a candidate transcriptional and signaling regulator in cancer.

   Evidence shRNA knockdown, xenograft models, ChIP/binding assays (breast cancer); Co-IP with RASA4, cell cycle analysis, xenograft (NSCLC)

   PMID:29053395 PMID:29249663

   Open questions at the time

   • The RASA4 interaction rests on a single Co-IP without reciprocal validation
   • How a small protein without canonical DNA-binding domains engages upstream regulatory sequences is unresolved
   • Whether these cancer phenotypes relate to JPT2's Ca²⁺ signaling role is unknown
3. 2019 Medium

   Mechanistic dissection in hepatocellular carcinoma revealed that JPT2 transcriptionally upregulates METTL13 through AP-2γ, which in turn drives proliferation and EMT via TCF3/ZEB1, placing JPT2 at the top of a defined transcriptional cascade promoting metastasis.

   Evidence shRNA knockdown, overexpression, in vivo xenograft, chromatin/transcription analysis in HCC cell lines

   PMID:30778199

   Open questions at the time

   • The molecular mechanism by which JPT2 activates AP-2γ-dependent transcription is not defined
   • Whether JPT2's transcriptional role requires its NAADP-binding capacity is untested
4. 2020 Medium

   Identification of HSPA9 as a JPT2-interacting partner and HMGB1 as a downstream effector provided an additional molecular axis through which JPT2 promotes breast cancer invasion and metastasis.

   Evidence Mass spectrometry, co-immunoprecipitation, functional invasion/metastasis assays with shRNA knockdown

   PMID:33191617

   Open questions at the time

   • The HSPA9 interaction was identified by a single MS/Co-IP study from one laboratory
   • How HSPA9 binding leads to HMGB1 expression change is mechanistically undefined
   • Relationship to NAADP/Ca²⁺ signaling axis is unexplored
5. 2021 High

   Two concurrent landmark studies resolved a decades-old question in Ca²⁺ signaling by identifying JPT2 as the direct NAADP-binding protein that transduces NAADP signals into Ca²⁺ release — JPT2 associates with TPCs to mediate Ca²⁺ release from acidic organelles and with RYR1 to trigger ER Ca²⁺ release, governing Ca²⁺ microdomains essential for T cell activation and endolysosomal trafficking including coronaviral entry.

   Evidence Clickable NAADP photoaffinity probe on recombinant protein, gene knockout in Jurkat and primary T cells, Ca²⁺ microdomain imaging, co-immunoprecipitation with RYR1 and TPCs, SARS-CoV-2 pseudovirus entry assays

   PMID:33758061 PMID:33758062

   Open questions at the time

   • Structural basis of NAADP binding by JPT2 is unknown — no crystal or cryo-EM structure exists
   • How JPT2 switches between TPC and RYR1 association is not defined
   • Whether JPT2's nuclear/transcriptional roles are mechanistically independent of NAADP binding remains unresolved

• The relationship between JPT2's well-established NAADP/Ca²⁺ signaling function and its reported transcriptional activities in cancer remains entirely unresolved — whether these represent genuinely distinct functions or are linked through Ca²⁺-dependent mechanisms is unknown.
• No structural model of JPT2 or its NAADP-binding domain exists
• Whether cancer-associated transcriptional phenotypes require NAADP binding or Ca²⁺ signaling has not been tested
• The stoichiometry and dynamics of JPT2 within TPC and RYR complexes are uncharacterized